A Case of Relentless CMV Viremia Two Years Post Kidney Transplant (NKF-SCM 2025) - Mar 13, 2025 - Abstract #G-080; "Mycophenolate mofetil was held, valganciclovir treatment dose was started...Unfortunately, she had a persistent CMV PCR on letermovir and she was switched maribavir, which initially controlled CMV viremia to undetectable. By 1 year, she developed CMV IgG yet had positive CMV requiring valganciclovir with filgrastim which provided remission for 7 months...Patient has remained on low level tacrolimus (goal 4-7ng/ml) and prednisone 5mg since first detection of CMV viremia and every time her antiviral was held for a few weeks, she had a significant and symptomatic rebound of CMV viremia and as to this date (2 years post-transplant) requires antiviral therapy...This case highlights the unusually persistent, rebounding, and relapsing course of infection. Management of this patient required a variety of prolonged antiviral therapy while balancing efficacy with toxicity.Conclusion This case underscores the importance of monitoring and treatment strategies in cases that may..."
Clinical • Hematological Disorders • Infectious Disease • Leukopenia • Transplantation
|
|
Dylan Clapp 1; Michael Purdon 1; Jaymin Patel 1; Niralee Patel 1
|